Literature DB >> 26936022

A comparison of intranasal dexmedetomidine for sedation in children administered either by atomiser or by drops.

B L Li1, N Zhang1, J X Huang1, Q Q Qiu1, H Tian1, J Ni1, X R Song1, V M Yuen2, M G Irwin3.   

Abstract

Intranasal dexmedetomidine has been used successfully for sedation in children. A mucosal atomisation device delivers an atomised solution to the nasal mucosa which facilitates rapid and effective delivery of medication to the systemic circulation. We compared intranasal delivery of dexmedetomidine in a dose of 3 μg.kg(-1) by either atomiser or drops from a syringe in children < 3 years old undergoing transthoracic echocardiography. Two hundred and seventy-nine children were randomly assigned to one or other group. One hundred and thirty-seven children received dexmedetomidine by atomiser and 142 by drops. The successful sedation rate was 82.5% (95% CI 75.3-87.9%) and 84.5% (95% CI 77.7-89.5%) for atomiser and drops, respectively (p = 0.569). Sedation tended to be less successful in older children (p = 0.028, OR 0.949, 95% CI 0.916-0.983). There were no significant complications. We conclude that both modes of dexmedetomidine administration are equally effective, although increasing age of the child was associated with a decreased likelihood of successful sedation.
© 2016 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Keywords:  atomizer; drops; intranasal dexmedetomidine; paediatric; sedation

Mesh:

Substances:

Year:  2016        PMID: 26936022     DOI: 10.1111/anae.13407

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  9 in total

1.  A Comparison of Intranasal Dexmedetomidine and Dexmedetomidine Plus Buccal Midazolam for Non-painful Procedural Sedation in Children with Autism.

Authors:  Bi Lian Li; Vivian Man-Ying Yuen; Na Zhang; Huan Huan Zhang; Jun Xiang Huang; Si Yuan Yang; Jeffery W Miller; Xing Rong Song
Journal:  J Autism Dev Disord       Date:  2019-09

Review 2.  Dexmedetomidine in paediatric anaesthesia.

Authors:  R Lin; J M Ansermino
Journal:  BJA Educ       Date:  2020-07-22

Review 3.  Intranasal Dexmedetomidine for Procedural Sedation in Children, a Suitable Alternative to Chloral Hydrate.

Authors:  Giorgio Cozzi; Stefania Norbedo; Egidio Barbi
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

4.  Intranasal Dexmedetomidine for the Treatment of Pre-operative Anxiety and Insomnia: A Prospective, Randomized, Controlled, and Clinical Trial.

Authors:  Wen Zeng; Li Chen; Xin Liu; Xujiang Deng; Kuan Huang; Maolin Zhong; Shubao Zhou; Lifang Zhan; Yulu Jiang; Weidong Liang
Journal:  Front Psychiatry       Date:  2022-05-30       Impact factor: 5.435

5.  The Sedative Effects of Inhaled Nebulized Dexmedetomidine on Children: A Systematic Review and Meta-Analysis.

Authors:  Jun Lin; Chujun Wu; Dizhou Zhao; Xuhang Du; Wangzhi Zhang; Jieyu Fang
Journal:  Front Pediatr       Date:  2022-05-20       Impact factor: 3.569

Review 6.  Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.

Authors:  Maud A S Weerink; Michel M R F Struys; Laura N Hannivoort; Clemens R M Barends; Anthony R Absalom; Pieter Colin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

Review 7.  Recent Advances in the Clinical Value and Potential of Dexmedetomidine.

Authors:  Xiaotian Liu; Yueqin Li; Li Kang; Qian Wang
Journal:  J Inflamm Res       Date:  2021-12-30

8.  Perioperative Low Dose Dexmedetomidine and Its Effect on the Visibility of the Surgical Field for Middle Ear Microsurgery: A Randomised Controlled Trial.

Authors:  Jinhong Wu; Yuan Han; Yu Lu; Yan Zhuang; Wenxian Li; Ji'e Jia
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

9.  Using intranasal dexmedetomidine with buccal midazolam for magnetic resonance imaging sedation in children: A single-arm prospective interventional study.

Authors:  Bi Lian Li; Hao Luo; Jun Xiang Huang; Huan Huan Zhang; Joanna R Paquin; Vivian M Yuen; Xing Rong Song
Journal:  Front Pediatr       Date:  2022-08-04       Impact factor: 3.569

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.